Combined portal and hepatic vein embolisation in perihilar cholangiocarcinoma
Smits, Jens Chau, Steven James, Sinéad Korenblik, Remon Tschögl, Madita Arntz, Pieter Bednarsch, Jan Abreu de Carvalho, Luis Detry, Olivier Erdmann, Joris
Smits, Jens
Chau, Steven
James, Sinéad
Korenblik, Remon
Tschögl, Madita
Arntz, Pieter
Bednarsch, Jan
Abreu de Carvalho, Luis
Detry, Olivier
Erdmann, Joris
Citations
Altmetric:
Affiliation
Other Contributors
Dasari, Bobby Vm
Mehrzad, Homoyon
Mehrzad, Homoyon
Publication date
2024-07-16
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background: Major hepatectomy in perihilar cholangiocarcinoma (pCCA) patients with a small future liver remnant (FLR) risks posthepatectomy liver failure (PHLF). This study examines combined portal and hepatic vein embolisation (PVE/HVE) to increase preoperative FLR volume and potentially decrease PHLF rates.
Methods: In this retrospective, multicentre, observational study, data was collected from centres affiliated with the DRAGON Trials Collaborative and the EuroLVD registry. The study included pCCA patients who underwent PVE/HVE between July 2016 and January 2023.
Results: Following PVE/HVE, 28% of patients (9/32) experienced complications, with 22% (7/32) necessitating biliary interventions for cholangitis. The median degree of hypertrophy after a median of 16 days was 16% with a kinetic growth rate of 6.8% per week. 69% of patients (22/32) ultimately underwent surgical resection. Cholangitis after PVE/HVE was associated with unresectability. After resection, 55% of patients (12/22) experienced complications, of which 23% (5/22) were Clavien-Dindo grade III or higher. The 90-day mortality after resection was 0%.
Conclusion: PVE/HVE quickly enhances the kinetic growth rate in pCCA patients. Cholangitis impairs chances on resection significantly. Resection after PVE/HVE is associated with low levels of 90-day mortality. The study highlights the potential of PVE/HVE in improving safety and outcomes in pCCA undergoing resection.
Citation
Smits J, Chau S, James S, Korenblik R, Tschögl M, Arntz P, Bednarsch J, Abreu de Carvalho L, Detry O, Erdmann J, Gruenberger T, Hermie L, Neumann U, Sandström P, Sutcliffe R, Denys A, Melloul E, Dewulf M, van der Leij C, van Dam RM; EuroLVD and DRAGON Trials Collaborative. Combined portal and hepatic vein embolisation in perihilar cholangiocarcinoma. HPB (Oxford). 2024 Dec;26(12):1458-1466. doi: 10.1016/j.hpb.2024.07.407. Epub 2024 Jul 16.
Type
Article